Synthon’s Rivastigmine approval forms part of a rich pipeline of research projects and pending regulatory applications and is another example of its strategy to bring affordable quality alternatives to innovative products to market at the earliest possible date.
Rivastigmine tartrate is the active ingredient of Novartis’ branded product Exelon®, which is one of the leading drugs for Alzheimer disease. Exelon® is indicated for symptomatic treatment of mild to moderately severe Alzheimer’s dementia and for the symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease. In Europe, sales of Rivastigmine were € 297 million in 2008 with 18 % annual growth (IMS Midas data).
About Synthon
Synthon is a generic pharmaceutical company whose activities range from the chemical development and production of active substances to the pharmaceutical development, manufacturing and packaging of finished dosage forms.
The company is headquartered in the Netherlands with subsidiary companies in the USA, Chile, Australia, Argentina, Czech Republic and Spain. Synthon’s modern international API and drug product manufacturing facilities are EU-GMP and FDA approved. Synthon licenses its products out to marketing partners in many countries worldwide.
For further information on Synthon and its products, please visit www.synthon.com.
Exelon® is a registered trademark of Novartis.